Immunotherapy, consisting mainly of immune checkpoint inhibitors, has been successfully employed in the treatment of early and advanced-stage melanoma for more than ten years. Personalized mRNA vaccines represent the next evolutionary step, offering patients a treatment unique to them and their tumor, whilst putting recent, significant technological and scientific advances into practice. Clinical and preclinical data about mRNA vaccines are now emerging, further encouraging research and spreading enthusiasm among patients and physicians. Nonetheless, a lot remains to be discovered about mRNA vaccines’ mechanisms of action, their actual effect on the immune cells of the patient, and successful mRNA delivery to the host.

Source:

Gazouli I, Bafaloukos D, Koutserimpas C, Samonis G. Individualized mRNA Vaccines in Melanoma—Where Do We Stand? Vaccines. 2025; 13(9):986. https://doi.org/10.3390/vaccines13090986

https://www.mdpi.com/2076-393X/13/9/986